Possibilities for IPM Strategies in European Laying Hen Farms for Improved Control of the Poultry Red Mite (Dermanyssus gallinae): Details and State of Affairs.

The Poultry Red Mite (PRM), Dermanyssus gallinae, is a major threat to the poultry industry worldwide, causing serious problems to animal health and welfare, and huge economic losses. Controlling PRM infestations is very challenging. Conventionally, D. gallinae is treated with synthetic acaricides, but the particular lifestyle of the mite (most of the time spent off the host) makes the efficacy of acaracide sprays often unsatisfactory, as sprays reach only a small part of the population. Moreover, many acaricides have been unlicensed due to human consumer and safety regulations and mites have become resistant to them. A promising course of action is Integrated Pest Management (IPM), which is sustainable for animals, humans and the environment. It combines eight different steps, in which prevention of introduction and monitoring of the pest are key. Further, it focusses on non-chemical treatments, with chemicals only being used as a last resort. Whereas IPM is already widely applied in horticulture, its application is still in its infancy to control D. gallinae in layer houses. This review presents the currently-available possibilities for control of D. gallinae in layer houses for each of the eight IPM steps, including monitoring techniques, established and emerging non-chemical treatments, and the strategic use of chemicals. As such, it provides a needed baseline for future development of specific IPM strategies, which will allow efficient and sustainable control of D. gallinae in poultry farms.

Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.

Since the publication of this paper the authors noticed an error in the listed authors, where Alexandros Siskos was listed as Alexandros Sitkos. This has now been corrected.

A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.

A 47-year-old man with metastatic melanoma presented with refractory hyperlactaemic acidosis following the first dose of the mono-carboxylase transporter 1 inhibitor AZD3965 within a "first time in man" clinical trial. The mechanism of the agent and the temporal relationship suggested that this event was potentially drug related and recruitment was suspended. However, urinary metabolomics showed extensive abnormalities even prior to drug administration, leading to investigations for an underlying metabolic disorder. The lack of clinical symptoms from the elevated lactate and low blood glucose suggested a diagnosis of "hyper-Warburgism", where the high tumour burden was associated with extensive glucose uptake and lactate efflux from malignant cells, and the subsequent impact on blood biochemistry. This was supported by an FDG-PET scan showing extensive glucose uptake in numerous metastases and lack of uptake in the brain. A review of the literature showed 16 case reports of "hyper-Warburgism" in non-haematological malignancies, none of them with melanoma, with most associated with a poor outcome. The patient was treated symptomatically, but died 2 months later. The development of AZD3965 continues with the exclusion of patients with elevated plasma lactate at screening added to the protocol as a safety measure.Trial identification number ClinicalTrials.Gov. NCT01791595.